GLP-1 and energy balance: an integrated model of short-term and long-term control
Authors:
- 7 June 2011
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 7 (9) , 507-516
Abstract
The authors of this Review integrate contributions of both central and peripheral glucagon-like peptide 1 (GLP-1), which is secreted from the intestine in response to nutrient ingestion, in a model of short-term and long-term control of energy balance. This model is discussed with respect to current GLP-1-based therapies and ongoing research that may help maximize the effectiveness of GLP-1-based treatment of obesity. Glucagon-like peptide 1 (GLP-1), a peptide secreted from the intestine in response to nutrient ingestion, is perhaps best known for its effect on glucose-stimulated insulin secretion. GLP-1 is also secreted from neurons in the caudal brainstem, and it is well-established that, in rodents, central administration of GLP-1 potently reduces food intake. Over the past decade, GLP-1 has emerged not only as an essential component of the system that regulates blood glucose levels but also as a viable therapeutic target for the treatment of type 2 diabetes mellitus. However, although GLP-1 receptor agonists are known to produce modest but statistically significant weight loss in patients with diabetes mellitus, our knowledge of how endogenous GLP-1 regulates food intake and body weight remains limited. The purpose of this Review is to discuss the evolution of our understanding of how endogenous GLP-1 modulates energy balance. Specifically, we consider contributions of both central and peripheral GLP-1 and propose an integrated model of short-term and long-term control of energy balance. Finally, we discuss this model with respect to current GLP-1-based therapies and suggest ongoing research in order to maximize the effectiveness of GLP-1-based treatment of obesity.Keywords
This publication has 130 references indexed in Scilit:
- Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled studyDiabetes, Obesity and Metabolism, 2010
- Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous systemAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne–Mendel rats compared to obesity-resistant S5B/Pl ratsInternational Journal of Obesity, 2010
- Immune challenge and satiety-related activation of both distinct and overlapping neuronal populations in the brainstem indicate parallel pathways for viscerosensory signalingBrain Research, 2009
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- The effects of GLP-1 infusion in the hepatic portal region on food intakeRegulatory Peptides, 2009
- Glucocorticoid regulation of preproglucagon transcription and RNA stability during stressProceedings of the National Academy of Sciences, 2009
- Do Incretins Play a Role in the Remission of Type 2 Diabetes after Gastric Bypass Surgery: What are the Evidence?Obesity Surgery, 2008
- Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*Diabetes, Obesity and Metabolism, 2008
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006